Tony Fong is managing editor for 360Dx, GenomeWeb's news site on the in vitro diagnostics market.
Centogene opened a Boston office in December and plans to open a lab there in a few months as it awaits an FDA decision on its clinical tool.
Winship's director of the cancer tissue and pathology shared resource said that some labs aren't leveraging molecular technologies due to reimbursement issues.
While molecular testing is now routine in cancer and women's health, for other disease areas, the technology may be overkill, Sundin said.
With recent and impending launches of POC MDx platforms, some industry observers believe the technology could replace some POC immunoassays in a few years.
The Singaporean molecular diagnostics firm, which went into judicial management in March, has new financial backing from a Chinese pharmaceutical firm.
Launched in April, the Japan Agency for Medical Research and Development is charged with streamlining that country's unwieldy funding process.
The firm will withdraw its planned IPO after being told that it would have to take a 30 to 40 percent discount to its valuation, its CEO said.
The firm aims to inform consumers about genomics and genetic testing, and open up opportunities for more patients to be included in cancer drug trials.
For every paid myBRCA test performed, the startup said that it will donate a free test.
The Belgian MDx firm's sights are set on assays for cancer, infectious disease, and sepsis, as well as new iterations of its flagship Idylla platform.
The US Department of Justice has proposed a rule change to enable DNA to be collected from migrants, the Associated Press reports.
Bernard Fisher, a surgeon who changed how breast cancer is treated, has died at 101, the New York Times reports.
A Washington Post columnist writes that she is skeptical about DNA-based diets.
In PNAS this week: recurrent inactivation of DEPDC5 in gastrointestinal stromal tumors, taxonomic reliability of GenBank sequences, and more.